Technical Analysis for COGT - Cogent Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| 200 DMA Resistance | Bearish | 9.88% | |
| Fell Below 20 DMA | Bearish | 9.88% | |
| MACD Bearish Signal Line Cross | Bearish | 9.88% | |
| 50 DMA Support | Bullish | 9.88% | |
| Bollinger Band Squeeze | Range Contraction | 9.88% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 9.88% | |
| Lower Bollinger Band Touch | Weakness | 9.88% |
| Alert | Time |
|---|---|
| Up 10% | 2 days ago |
| 60 Minute Opening Range Breakout | 2 days ago |
| Rose Above 10 DMA | 2 days ago |
| Up 1 ATR | 2 days ago |
| 10 DMA Resistance | 2 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Cogent's most advanced program, PLX9486, is a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent is headquartered in Cambridge, MA.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Disease Gastrointestinal Enzymes Protein Kinase Inhibitor Tyrosine Kinase Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Imatinib Gastrointestinal Stromal Tumors
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Disease Gastrointestinal Enzymes Protein Kinase Inhibitor Tyrosine Kinase Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Imatinib Gastrointestinal Stromal Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.5 |
| 52 Week Low | 3.67 |
| Average Volume | 1,255,717 |
| 200-Day Moving Average | 7.71 |
| 50-Day Moving Average | 7.05 |
| 20-Day Moving Average | 7.71 |
| 10-Day Moving Average | 7.84 |
| Average True Range | 0.58 |
| RSI (14) | 55.75 |
| ADX | 18.82 |
| +DI | 21.60 |
| -DI | 24.71 |
| Chandelier Exit (Long, 3 ATRs) | 6.72 |
| Chandelier Exit (Short, 3 ATRs) | 8.19 |
| Upper Bollinger Bands | 8.30 |
| Lower Bollinger Band | 7.12 |
| Percent B (%b) | 0.75 |
| BandWidth | 15.35 |
| MACD Line | 0.24 |
| MACD Signal Line | 0.26 |
| MACD Histogram | -0.0221 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.35 | ||||
| Resistance 3 (R3) | 9.25 | 8.72 | 9.12 | ||
| Resistance 2 (R2) | 8.72 | 8.38 | 8.76 | 9.05 | |
| Resistance 1 (R1) | 8.36 | 8.17 | 8.54 | 8.46 | 8.97 |
| Pivot Point | 7.83 | 7.83 | 7.92 | 7.87 | 7.83 |
| Support 1 (S1) | 7.47 | 7.49 | 7.65 | 7.57 | 7.05 |
| Support 2 (S2) | 6.94 | 7.28 | 6.98 | 6.97 | |
| Support 3 (S3) | 6.58 | 6.94 | 6.90 | ||
| Support 4 (S4) | 6.68 |
